CALGARY, Alberta – (October 3, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) highlights recent a meta-analysis which re-evaluated the strength of the link between serotonin levels and depression.
According to the study published in Nature Molecular Psychiatry on July 20, 2022 1, despite the influence of the serotonin theory of depression, there was no comprehensive review of the scientific literature undertaken, despite the various known facts of the patients taking selective serotonin reuptake inhibitors (SSRIs):
- Up to 30% subject patients not responding to the treatment
- Effectiveness of the treatment can take up to 4 weeks
- Up to 40% of patients who respond to treatment become apathetic or lose overall motivation
“The lack of a link between depression and serotonin levels found by the authors is a concern, as this original hypothesis led to the introduction of the widest prescribed class of anti-depressant drugs to date, the SSRIs,” said Dr. Mark Williams, Chief Science Officer of Marvel Biosciences.” We have been investigating our lead candidate MB204, a novel adenosine A2a receptor (A2aR) antagonist for the treatment of depression, which does not involve the serotonin pathway.”
In pre-clinical studies the MB-204:
- Reduced depressive symptoms by >80% (p<0.0001) in a forced swim test
- Proved to be effective within one hour of oral dosing
“We also believe MB204 could be a potential treatment for Alzheimer’s Disease (“AD”) as research has been strengthening on the role of the A2aR in AD. Noticeably, up to 40% of AD patients suffer from depression, which may worsen their dementia,” said Rod Matheson, CEO of Marvel Biosciences. “The recent success of Biogen (Nasdaq: BIIB) and Eisai’s (TSE: 4523) drug for AD is going to garner renew interest in the AD space, and we hope to position MB204 as a highly attractive candidate for the treatment of AD while also treating its frequently associated depression”.
- Moncrieff, J., Cooper, R.E., Stockmann, T. et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry (2022).
Investor Relations: Marvel Biosciences Corp.
Virtus Advisory Group Roderick (Rod) Matheson, Chief Executive Officer or
Tel: 416-644-5081 Dr. Mark Williams, President, and Chief Science Officer
Tel: 403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.